Press releases

(French) Infection VIH par voie sexuelle : élucidation de mécanismes-clé chez l’homme

19 Feb 2013 | By Inserm (Newsroom) | Immunology, inflammation, infectiology and microbiology

The HOMAGE (Heart OMics in AGEing) project, coordinated by the French National Institute of Health and Medical Research (INSERM), has been awarded a grant by the European Commission for a 6 year period. The project aims to identify and validate specific biomarkers of heart failure in order to prevent the development of the disease affecting elderly population. 17 research groups from 10 countries will collaborate to investigate new ways of preventing heart failure. The project will use an innovative ‘omic-based’ approach which investigating simultaneously a huge amount of genes, proteins and metabolites.

The 17 partners will meet at Nancy on February 22nd for the kick off meeting of HOMAGE.

Professor Faiez Zannad, Head of the Centre d’Investigation Clinique Pierre Drouin Inserm U9501 and Inserm Unit 1116 based in Nancy, is the project coordinator.  The 12 million euros grant of the European Commission will be dedicated to the HOMAGE consortium for research on heart failure, a serious illness altering myocardial activity which affects more than 6.5 million persons in Europe. Indeed, the prevalence of heart failure is increasing worldwide due to an ageing population as well as a rising trend of risk factors for heart disease such as diabetes, obesity and hypertension.

Heart failure is a major cause of mortality and morbidity in the world and remains the most frequent cause of hospitalization for patients over 65 years old.

The costs related to heart failure have been estimated around 1.5 billion euros per year in France[1].

Photo : ©Serimedis/Inserm

Despite important progress in the treatment including new drugs, new medical devices and innovative disease management programmes, the diagnosis of heart failure is often difficult in older adults with co-morbidities. Screening tests are usually based on blood pressure, glycaemic and cholesterol control. Although they are useful to detect high risk patients, they are limited regarding their sensitivity and specificity. During the past decade, promising biomarkers such as natriuretic peptides have been identified to diagnose heart failure, but their predictive value remains relatively poor. The HOMAGE consortium is willing to validate more specific and more sensitive biomarkers which should facilitate an early detection of the disease in patients at risk.

To achieve this goal, the consortium agreed on the use of an ‘omic-based’ approach. This approach aims to validate promising biomarker candidates by crossing a large volume of data (genomics, proteomics, miRNomics, transcriptomics and metabolomics). This would permit scientists to understand new pathophysiological mechanisms, signaling pathways and identify new therapeutic targets to prevent heart failure.

The HOMAGE consortium will manage cohorts for a total of 30 000 patients. The European researchers will firstly identify biomarker candidates in blood and study their predictive value for heart failure and common co-morbidities associated with ageing (renal impairment, cognitive disorders…). Subsequently, HOMAGE will lead a clinical trial to look for novel treatments of heart failure that can be targeted specifically to those patients at risk.

This trial will allow identifying patients’ omics based biomarker profiles most likely to predict response to treatment with the better benefit/risk ratio, an attempt into personalized medicine.

[1] Fédération Française de Cardiologie

The 17 partners of HOMAGE project : (en ligne le 21 février)

Inserm, France :

Inserm U942/ Biomarqueurs et maladies cardiaques, France

Inserm UMR 1048/ Equipe 7, France

Inserm U744/ Recherche des Déterminants Moléculaires des Maladies Cardiovasculaires, France

Inserm Transfert, France :

European Drug Development Hub, France :

ACS Biomarker, Pays-Bas :

Randox Testing Service, Royaume-Uni :

Medical University of Graz, Autriche :

University of Manchester, Royaume-Uni :

Fundación para la Investigación Médica Aplicada, Espagne :

University College Dublin, Irlande :

University of Hull, Royaume-Uni :

Maastricht University, Pays-Bas :

Istituto di Ricerche Farmacologiche ‘Mario Negri’, Italie :

Hannover Medical School, Allemagne :

University of Leuven, Belgique :

London School of Hygiene, Royaume-Uni :

Emory University, Etats Unis :

University of Glasgow, Royaume-Uni :

Collaborative institutions:

The Trustees of Boston University, National Heart, Lung, and Blood Institute’s Framingham Heart Study, Etats Unis

Imperial College, Royaume-Uni

Steno Diabetes Center (Novo Nordisk), Danemark

Researcher Contact
Morgane Bomsel 01 40 51 64 97 rf.mresni@lesmob.enagrom
Press Contact
Presse CNRS Laetitia Louis 01 44 96 51 37 rf.rid-srnc@siuol.aititeal
The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages Y Ganor, Z Zhou, J Bodo, D Tudor, J Leibowitch, D Mathez, A Schmitt, M-C Vacher-Lavenu, M Revol and M Bomsel, received 14 June 2012; accepted 17 October 2012; advance online publication 28 November 2012. doi:10.1038/mi.2012.116